These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16720861)

  • 1. Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
    Tarhini AA; Shipe-Spotloe J; DeMark M; Agarwala SS; Kirkwood JM
    Oncologist; 2006 May; 11(5):538-9; author reply 539-40. PubMed ID: 16720861
    [No Abstract]   [Full Text] [Related]  

  • 2. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b.
    Hurley KE; Chapman PB
    Oncologist; 2005 Oct; 10(9):739-42. PubMed ID: 16249355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
    Gogas H; Bafaloukos D; Ioannovich J; Skarlos D; Polyzos A; Fountzilas G; Kalofonos HP; Aravantinos G; Tsoutsos D; Panagiotou P; Frangia K; Petrakopoulou T; Pectasides D;
    Anticancer Res; 2004; 24(3b):1947-52. PubMed ID: 15274382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recombinant interferon alfa-2b in the treatment of patients with skin melanoma].
    Korovin SI
    Lik Sprava; 1998; (2):139-41. PubMed ID: 9670687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point: Interferon-alpha for adjuvant therapy for melanoma patients.
    Sabel MS; Sondak VK
    J Natl Compr Canc Netw; 2004 Jan; 2(1):61-8. PubMed ID: 19777695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patients.
    Chapman PB
    J Natl Compr Canc Netw; 2004 Jan; 2(1):69-72. PubMed ID: 19777696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of adjuvant interferon-alpha low-dose therapy in melanoma patients on serum inhibin B.
    Karamfilov T; Wollina U; Hipler UC; Graefe T; Schreiber G
    J Dermatol; 2000 Oct; 27(10):639-42. PubMed ID: 11092267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Feasability and tolerance of adjuvant treatment of melanoma with immunotherapy according to Kirkwood protocol].
    Uwer L; Martin S; Geoffrois L; Schmutz JL
    Ann Dermatol Venereol; 2005 Jan; 132(1):50-1. PubMed ID: 15746611
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Endolymphatic therapy in the treatment of primary delimited melanoblastoma of the skin].
    Korovin SI
    Klin Khir; 1998; (1):39-40. PubMed ID: 9615056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
    Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
    Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 19. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of adjuvant interferon in high risk melanoma patients.
    Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.